Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)

National Institutes of Health
Award Not specified
Closing date 164 days left · Sep 07, 2026
Location Global
For Orgs

About this opportunity

This funding opportunity announcement encourages applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This is an R21 grant mechanism that allows for clinical trials as an optional component.
research Alzheimer's disease dementia neuropsychiatric symptoms aging research neurobiology biobehavioral pathways therapeutic targets mental health ADRD

Who can apply

Applicant Types

organization

Organization Types

nonprofit, for profit, academic, government, tribal

Project Locations

🇺🇸 United States

Region

United States

How to apply

Stages

  1. 1 single_stage

External listing — not managed by a verified Grantory funder

External Application

This opportunity requires you to apply directly on the funder's website.

Apply on External Site

AI-Extracted Data

This opportunity was automatically extracted from an external source using AI. Details such as amounts, closing dates, and eligibility may be incomplete or inaccurate.

Always verify on the official source

Similar opportunities

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)

Great match

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies tha...

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Great match

The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle indep...

Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed)

Great match

The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innova...

Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)

Great match

Although the majority living with schizophrenia and related disorders are over 35 years old, includi...